<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal;
font-family:"Verdana","sans-serif";
color:windowtext;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>See below for a number of articles that were passed to me by one of the Chairs of another PCCN group.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><i><span lang=EN-US style='font-family:"Verdana","sans-serif"'>.<o:p></o:p></span></i></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'>Trillium Drug Program: during our May meeting on access to drugs, the Trillium Program came up. For those, like me, who didn’t know about it, here is a quick introduction. <br></span><span lang=EN-US><a href="https://www.hmabenefits.ca/blog/drugs-dental-what-does-the-trillium-drug-plan-cover-your-blog-post-title-here">https://www.hmabenefits.ca/blog/drugs-dental-what-does-the-trillium-drug-plan-cover-your-blog-post-title-here</a></span><span lang=EN-US style='font-family:"Verdana","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'>Active Surveillance: we all know that men don’t like to go to the doctor but it becomes a bit ridiculous when they won’t even keep up their monitoring program after opting for Active Surveillance. “<i>Just 15 percent of a group of men in North Carolina with early-stage prostate cancer who chose active surveillance instead of treatment followed the recommended monitoring guidelines</i>”.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><a href="https://www.eurekalert.org/pub_releases/2019-05/ulcc-mwc053119.php">https://www.eurekalert.org/pub_releases/2019-05/ulcc-mwc053119.php</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'>Drug Combinations: if Xtandi (enzalutamide) works one way and Zytiga (abiraterone) works another way to combat metastatic PC, then a combination of the two must be even better – right? Unfortunately, that doesn’t seem to be the case (not that many people could afford that duo anyway.) <i>"Overall, the study shows that more is not better in first-line metastatic therapy"<br></i></span><span lang=EN-US><a href="https://www.medpagetoday.com/meetingcoverage/asco/80187?xid=nl_mpt_DHE_2019-06-03&eun=g675885d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202019-06-03&utm_term=NL_Daily_DHE_Activealter">https://www.medpagetoday.com/meetingcoverage/asco/80187?xid=nl_mpt_DHE_2019-06-03&eun=g675885d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202019-06-03&utm_term=NL_Daily_DHE_Activealter</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'>Prostate Cancer Consists of Multiple Tumours: “</span><i><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:black;background:white'>Most primary prostate cancers consist of multiple tumors within the same organ, but little is known about their relationships. We have compared the sets of gene mutations among such tumors and found that they only exceptionally have any in common</span></i><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:black;background:white'>”</span><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:black;background:white'>. </span><span lang=EN-US><a href="https://www.ncbi.nlm.nih.gov/pubmed/30181068">https://www.ncbi.nlm.nih.gov/pubmed/30181068</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'>This, of course, is why some doctors prefer to treat the whole organ rather than try ‘focal therapy’ on the prostate.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'>Focal Therapy: however, the above does not mean that focal therapy might not be right for some men. Here is another approach </span><i><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif"'>“<span style='color:#333333;background:white'>Researchers have shown that selectively destroying cancerous prostate tissue is as effective as complete prostate removal”<o:p></o:p></span></span></i></p><p class=MsoNormal><span lang=EN-US><a href="https://www.sciencedaily.com/releases/2019/03/190320132051.htm">https://www.sciencedaily.com/releases/2019/03/190320132051.htm</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'>ADT Side Effects; most men have some degree of side effects from ADT and are told that they should exercise more.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-family:"Verdana","sans-serif"'>Here is the abstract of a study that concludes that “</span><i><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:black;background:white'>diet and physical activity intervention can minimize the adverse body composition changes associated with ADT” </span></i><span lang=EN-US><a href="https://www.ncbi.nlm.nih.gov/pubmed/25916660">https://www.ncbi.nlm.nih.gov/pubmed/25916660</a><o:p></o:p></span></p><p class=MsoNormal><i><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'><o:p> </o:p></span></i></p></div></body></html>